These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 27723970)

  • 1. Glutathione-Sensitive Hyaluronic Acid-SS-Mertansine Prodrug with a High Drug Content: Facile Synthesis and Targeted Breast Tumor Therapy.
    Zhong P; Zhang J; Deng C; Cheng R; Meng F; Zhong Z
    Biomacromolecules; 2016 Nov; 17(11):3602-3608. PubMed ID: 27723970
    [TBL] [Abstract][Full Text] [Related]  

  • 2. α
    Zhong P; Gu X; Cheng R; Deng C; Meng F; Zhong Z
    Int J Nanomedicine; 2017; 12():7913-7921. PubMed ID: 29138558
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glutathione-Sensitive Hyaluronic Acid-Mercaptopurine Prodrug Linked via Carbonyl Vinyl Sulfide: A Robust and CD44-Targeted Nanomedicine for Leukemia.
    Qiu J; Cheng R; Zhang J; Sun H; Deng C; Meng F; Zhong Z
    Biomacromolecules; 2017 Oct; 18(10):3207-3214. PubMed ID: 28835099
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hyaluronic acid-shelled acid-activatable paclitaxel prodrug micelles effectively target and treat CD44-overexpressing human breast tumor xenografts in vivo.
    Zhong Y; Goltsche K; Cheng L; Xie F; Meng F; Deng C; Zhong Z; Haag R
    Biomaterials; 2016 Apr; 84():250-261. PubMed ID: 26851390
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hyaluronic Acid-Shelled Disulfide-Cross-Linked Nanopolymersomes for Ultrahigh-Efficiency Reactive Encapsulation and CD44-Targeted Delivery of Mertansine Toxin.
    Zhang Y; Wu K; Sun H; Zhang J; Yuan J; Zhong Z
    ACS Appl Mater Interfaces; 2018 Jan; 10(2):1597-1604. PubMed ID: 29272095
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Positron-Emission Tomography of HER2-Positive Breast Cancer Xenografts in Mice with
    Al-Saden N; Lam K; Chan C; Reilly RM
    Mol Pharm; 2018 Aug; 15(8):3383-3393. PubMed ID: 29957952
    [TBL] [Abstract][Full Text] [Related]  

  • 7. α
    Zhong P; Meng H; Qiu J; Zhang J; Sun H; Cheng R; Zhong Z
    J Control Release; 2017 Aug; 259():176-186. PubMed ID: 27986551
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reversibly crosslinked hyaluronic acid nanoparticles for active targeting and intelligent delivery of doxorubicin to drug resistant CD44+ human breast tumor xenografts.
    Zhong Y; Zhang J; Cheng R; Deng C; Meng F; Xie F; Zhong Z
    J Control Release; 2015 May; 205():144-54. PubMed ID: 25596560
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of HER2 positive advanced breast cancer with T-DM1: A review of the literature.
    Martínez MT; Pérez-Fidalgo JA; Martín-Martorell P; Cejalvo JM; Pons V; Bermejo B; Martín M; Albanell J; Lluch A
    Crit Rev Oncol Hematol; 2016 Jan; 97():96-106. PubMed ID: 26318092
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trastuzumab emtansine suppresses the growth of HER2-positive small-cell lung cancer in preclinical models.
    Morimura O; Minami T; Kijima T; Koyama S; Otsuka T; Kinehara Y; Osa A; Higashiguchi M; Miyake K; Nagatomo I; Hirata H; Iwahori K; Takimoto T; Takeda Y; Kida H; Kumanogoh A
    Biochem Biophys Res Commun; 2017 Jul; 488(4):596-602. PubMed ID: 28526406
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase 1 study of weekly dosing of trastuzumab emtansine (T-DM1) in patients with advanced human epidermal growth factor 2-positive breast cancer.
    Beeram M; Krop IE; Burris HA; Girish SR; Yu W; Lu MW; Holden SN; Modi S
    Cancer; 2012 Dec; 118(23):5733-40. PubMed ID: 22648179
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Engineered thio-trastuzumab-DM1 conjugate with an improved therapeutic index to target human epidermal growth factor receptor 2-positive breast cancer.
    Junutula JR; Flagella KM; Graham RA; Parsons KL; Ha E; Raab H; Bhakta S; Nguyen T; Dugger DL; Li G; Mai E; Lewis Phillips GD; Hiraragi H; Fuji RN; Tibbitts J; Vandlen R; Spencer SD; Scheller RH; Polakis P; Sliwkowski MX
    Clin Cancer Res; 2010 Oct; 16(19):4769-78. PubMed ID: 20805300
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer.
    Hurvitz SA; Dirix L; Kocsis J; Bianchi GV; Lu J; Vinholes J; Guardino E; Song C; Tong B; Ng V; Chu YW; Perez EA
    J Clin Oncol; 2013 Mar; 31(9):1157-63. PubMed ID: 23382472
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Feasibility and cardiac safety of trastuzumab emtansine after anthracycline-based chemotherapy as (neo)adjuvant therapy for human epidermal growth factor receptor 2-positive early-stage breast cancer.
    Krop IE; Suter TM; Dang CT; Dirix L; Romieu G; Zamagni C; Citron ML; Campone M; Xu N; Smitt M; Gianni L
    J Clin Oncol; 2015 Apr; 33(10):1136-42. PubMed ID: 25713436
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trastuzumab emtansine (T-DM1) for HER2-positive breast cancer.
    Boyraz B; Sendur MA; Aksoy S; Babacan T; Roach EC; Kizilarslanoglu MC; Petekkaya I; Altundag K
    Curr Med Res Opin; 2013 Apr; 29(4):405-14. PubMed ID: 23402224
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhanced antitumor activity of trastuzumab emtansine (T-DM1) in combination with pertuzumab in a HER2-positive gastric cancer model.
    Yamashita-Kashima Y; Shu S; Harada N; Fujimoto-Ouchi K
    Oncol Rep; 2013 Sep; 30(3):1087-93. PubMed ID: 23783223
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Antibody-drug conjugates in oncology: from the concept to trastuzumab emtansine (T-DM1)].
    Gonçalves A; Trédan O; Villanueva C; Dumontet C
    Bull Cancer; 2012 Dec; 99(12):1183-91. PubMed ID: 23247898
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trastuzumab-deBouganin Conjugate Overcomes Multiple Mechanisms of T-DM1 Drug Resistance.
    Dillon RL; Chooniedass S; Premsukh A; Adams GP; Entwistle J; MacDonald GC; Cizeau J
    J Immunother; 2016 Apr; 39(3):117-26. PubMed ID: 26938945
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potential mechanisms for thrombocytopenia development with trastuzumab emtansine (T-DM1).
    Uppal H; Doudement E; Mahapatra K; Darbonne WC; Bumbaca D; Shen BQ; Du X; Saad O; Bowles K; Olsen S; Lewis Phillips GD; Hartley D; Sliwkowski MX; Girish S; Dambach D; Ramakrishnan V
    Clin Cancer Res; 2015 Jan; 21(1):123-33. PubMed ID: 25370470
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trastuzumab Emtansine (T-DM1) in Patients With HER2-Positive Metastatic Breast Cancer Previously Treated With Chemotherapy and 2 or More HER2-Targeted Agents: Results From the T-PAS Expanded Access Study.
    Yardley DA; Krop IE; LoRusso PM; Mayer M; Barnett B; Yoo B; Perez EA
    Cancer J; 2015; 21(5):357-64. PubMed ID: 26389758
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.